Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

The Real Winner in the War Over 21st Century Fox Is … Netflix, Inc.?

By Dana Blankenhorn, InvestorPlace Contributor

The dance among Comcast, AT&T and Disney over entertainment assets will leave the winner weakened as it competes with Amazon and Google. And Netflix (NFLX) is ready to strike as it quietly surpasses each company.

Despite Growing Pains, Solar Stocks Have Inevitability Behind Them

By Dana Blankenhorn, InvestorPlace Contributor

China announced a sudden halt to new solar supplies, in order to ramp up storage, and solar stocks were hit hard.

There’s Still Nothing More Shaky Than a Bitcoin Investment

By Dana Blankenhorn, InvestorPlace Contributor

Cryptocurrency markets remain targets of fraud, and attempts to even create transparency are fiercely fought.

Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems

By Dana Blankenhorn, InvestorPlace Contributor

Valeant has put its scandals into the past and will change its name to Bausch, but it still has debt worth three times annual sales.

The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear

By Dana Blankenhorn, InvestorPlace Contributor

Regeneron trades at just 25.5 times earnings, despite 20% growth and an ability to bring as much as one-third of revenue to the bottom line. With pharma no longer out of fashion, buy REGN stock before the market pushes it higher.

Load More